BiotechTube

Nivolumab 100 MG in 10 ML Injection

Phase 2UNKNOWN
0 views this week 0 watching💤 Quiet
Interest: 31/100
31
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Upper Urinary Tract Urothelial Carcinoma

Conditions

Upper Urinary Tract Urothelial Carcinoma

Trial Timeline

Dec 25, 2020 → Dec 30, 2024

NCT ID
NCT05160285

About Nivolumab 100 MG in 10 ML Injection

Nivolumab 100 MG in 10 ML Injection is a phase 2 stage product being developed by Ono Pharmaceutical for Upper Urinary Tract Urothelial Carcinoma. The current trial status is unknown. This product is registered under clinical trial identifier NCT05160285. Target conditions include Upper Urinary Tract Urothelial Carcinoma.

What happened to similar drugs?

6 of 15 similar drugs in Upper Urinary Tract Urothelial Carcinoma were approved

Approved (6) Terminated (1) Active (9)
✅Remimazolam TosilateJiangsu Hengrui MedicineApproved
✅BOTOXAbbVieApproved
✅Montelukast + PlaceboMerckApproved
✅diclofenac potassium + nimesulideNovartisApproved
✅Diclofenac gelNovartisApproved
✅AboBoNT-A + OnaBoNT-AIpsenApproved
🔄Muntelukast + PlaceboMerckPhase 3

Hype Score Breakdown

Clinical
12
Activity
4
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT05160285Phase 2UNKNOWN

Competing Products

20 competing products in Upper Urinary Tract Urothelial Carcinoma

See all competitors
ProductCompanyStageHype Score
Remimazolam TosilateJiangsu Hengrui MedicineApproved
43
ABBV-950 + BOTOX + Placebo for ABBV-950AbbViePhase 1
21
BOTOX + Placebo for BOTOXAbbViePhase 2
35
BOTOXAbbVieApproved
43
MK-3475 and BCGMerckPhase 2
42
Montelukast + PlaceboMerckApproved
43
Muntelukast + PlaceboMerckPhase 3
36
IFF flavor 316 282, Paracetamol, PseudoephedrineNovartisPhase 3
40
Paracetamol (500 mg)/dimethindene maleate (1 mg)/ phenylephrine hydrochloride (10 mg) tablets + Paracetamol (500 mg) tabletsNovartisPhase 3
40
diclofenac potassium + nimesulideNovartisApproved
35
Diclofenac gelNovartisApproved
43
IFF flavor 316 282, Paracetamol , Phenylephrine, GuaifenesinNovartisPhase 3
40
Domvanalimab + Zimberelimab + Capecitabine + Fluorouracil + Leucovorin + Oxaliplatin + NivolumabGilead SciencesPhase 3
44
Azithromycin SRPfizerPhase 3
40
NivolumabBristol Myers SquibbPre-clinical
26
NivolumabBristol Myers SquibbPre-clinical
26
REGN475/SAR164877 + Placebo (for REGN475/SAR164877)Regeneron PharmaceuticalsPhase 2
27
IPN10200 + IPN10200 Placebo + DysportIpsenPhase 1/2
36
AboBoNT-A + OnaBoNT-AIpsenApproved
40
Botulinum toxin type AIpsenPhase 3
37